ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,942.47
1.26%
US Tech 100
20,762.73
1.73%
Dow Jones
42,732.13
0.80%
Brent Oil
76.495
0.00%
Bitcoin
98,315.20
0.11%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE

  6. Biopharma Credit Plc (BPCR) Quote

Biopharma Credit Plc

Biopharma Credit Plc (BPCR)

LSE
0.87
-0.002
(-0.23%)
Closed January 05 11:30AM
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
0.87
Bid
0.87
Ask
0.872
Volume
1,373,223
0.868 Day's Range 0.876
0.83 52 Week Range 0.942
Market Cap
1.04B
Previous Close
0.872
Open
0.876
Last Trade
1039
@
0.87
(UT)
Last Trade Time
Financial Volume
$ 1,194,979
VWAP
0.8702
Average Volume (3m)
1,047,206
Shares Outstanding
1,194,882,668
Dividend Yield
8.05%
PE Ratio
9.58
Earnings Per Share (EPS)
0.09
Revenue
135.74M
Net Profit
108.45M

About Biopharma Credit Plc

Sector
Finance Services
Industry
Finance Services
Headquarters
London, Ontario, Can
Founded
-
Biopharma Credit Plc is listed in the Finance Services sector of the London Stock Exchange with ticker BPCR. The last closing price for Biopharma Credit was $0.87. Over the last year, Biopharma Credit shares have traded in a share price range of $ 0.83 to $ 0.942.

Biopharma Credit currently has 1,194,882,668 shares outstanding. The market capitalization of Biopharma Credit is $1.04 billion. Biopharma Credit has a price to earnings ratio (PE ratio) of 9.58.

Ask ADVFN Intelligence (AI)

BPCR Latest News

More News

BioPharma Credit PLC Total Voting Rights

BioPharma Credit PLC 02 January 2025   BioPharma Credit plc (the "Company") TOTAL VOTING RIGHTS   In conformity with the Disclosure Guidance and Transparency Rules, the Company notifies the...

January 02 2025
RNS Regulatory News

BioPharma Credit PLC Transaction in Own Shares

BioPharma Credit PLC 02 January 2025   BioPharma Credit plc (the "Company") TRANSACTION IN OWN SHARES   BioPharma Credit PLC announces that on 31 December 2024 it had purchased the following...

January 02 2025
RNS Regulatory News

BioPharma Credit PLC Transaction in Own Shares

BioPharma Credit PLC 30 December 2024   BioPharma Credit plc (the "Company") TRANSACTION IN OWN SHARES   BioPharma Credit PLC announces that today it has purchased the following number of its...

December 30 2024
RNS Regulatory News

BioPharma Credit PLC Transaction in Own Shares

BioPharma Credit PLC 23 December 2024   BioPharma Credit plc (the "Company") TRANSACTION IN OWN SHARES   BioPharma Credit PLC announces that today it has purchased the following number of its...

December 23 2024
RNS Regulatory News

BioPharma Credit PLC Net Asset Value(s) and Monthly Factsheet

BioPharma Credit PLC 23 December 2024   BIOPHARMA CREDIT PLC (the 'Company')   As at the 30 November 2024 the unaudited net asset value per Ordinary Share, including current period revenue...

December 23 2024
RNS Regulatory News

BioPharma Credit PLC Transaction in Own Shares

BioPharma Credit PLC 20 December 2024   BioPharma Credit plc (the "Company") TRANSACTION IN OWN SHARES   BioPharma Credit PLC announces that today it has purchased the following number of its...

December 20 2024
RNS Regulatory News

BioPharma Credit PLC Director/PDMR Shareholding

BioPharma Credit PLC 17 December 2024   BIOPHARMA CREDIT PLC   Notification of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated with them   1...

December 17 2024
RNS Regulatory News

BioPharma Credit PLC Net Asset Value(s) and Monthly Factsheet

BioPharma Credit PLC 05 December 2024   BIOPHARMA CREDIT PLC (the 'Company')   As at the 31 October 2024 the unaudited net asset value per Ordinary Share, including current period revenue, was...

December 05 2024
RNS Regulatory News

BioPharma Credit PLC Holding(s) in Company

BioPharma Credit PLC 20 November 2024   TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00BDGKMY29 Issuer Name BIOPHARMA CREDIT PLC UK or Non-UK Issuer UK 2...

November 20 2024
RNS Regulatory News

BioPharma Credit PLC Holding(s) in Company

BioPharma Credit PLC 20 November 2024   TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00BDGKMY29 Issuer Name BIOPHARMA CREDIT PLC UK or Non-UK Issuer UK 2...

November 20 2024
RNS Regulatory News
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.0161.873536299770.8540.8840.8415362460.8650545DE
4-0.012-1.360544217690.8820.890.848914320.864034DE
12-0.01-1.136363636360.880.9080.8410472060.86712344DE
260.0182.112676056340.8520.940.8411224250.88538651DE
52-0.036-3.973509933770.9060.9420.8314734140.88736026DE
156-0.1-10.30927835050.971.050.8116677680.92437212DE
260-0.15-14.70588235291.021.050.8115271410.94269917DE

BPCR - Frequently Asked Questions (FAQ)

What is the current Biopharma Credit share price?
The current share price of Biopharma Credit is $ 0.87
How many Biopharma Credit shares are in issue?
Biopharma Credit has 1,194,882,668 shares in issue
What is the market cap of Biopharma Credit?
The market capitalisation of Biopharma Credit is USD 1.04B
What is the 1 year trading range for Biopharma Credit share price?
Biopharma Credit has traded in the range of $ 0.83 to $ 0.942 during the past year
What is the PE ratio of Biopharma Credit?
The price to earnings ratio of Biopharma Credit is 9.58
What is the cash to sales ratio of Biopharma Credit?
The cash to sales ratio of Biopharma Credit is 7.66
What is the reporting currency for Biopharma Credit?
Biopharma Credit reports financial results in USD
What is the latest annual turnover for Biopharma Credit?
The latest annual turnover of Biopharma Credit is USD 135.74M
What is the latest annual profit for Biopharma Credit?
The latest annual profit of Biopharma Credit is USD 108.45M
What is the registered address of Biopharma Credit?
The registered address for Biopharma Credit is LINK COMPANY MATTERS LIMITED, 6TH FLOOR, GRESHAM STREET, LONDON, ONTARIO, EC2V 7NQ
Which industry sector does Biopharma Credit operate in?
Biopharma Credit operates in the FINANCE SERVICES sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TCFTheracryf Plc
0.725p
(38.10%)
7.56M
NMTNeometals Ltd
3.50p
(27.27%)
346.81k
SCHOScholium Group Plc
44.00p
(25.71%)
30.65k
FABFusion Antibodies Plc
10.15p
(24.54%)
3.34M
PYXPyx Resources Limited
3.49p
(22.24%)
8.43k
TM1Technology Minerals Plc
0.125p
(-24.24%)
37.21M
QUIZQuiz Plc
0.70p
(-18.60%)
3.67M
SYMESupply@me Capital Plc
0.003p
(-17.81%)
168.35M
OBDOxford Biodynamics Plc
1.20p
(-14.29%)
827.83k
ZENZenith Energy Ltd.
5.25p
(-13.93%)
5.39M
TRPTower Resources Plc
0.0395p
(5.33%)
539.51M
CPXCap-xx Limited
0.1825p
(1.39%)
494M
NTVONativo Resources Plc
0.0019p
(0.00%)
320.16M
DGIDg Innovate Plc
0.0225p
(-13.46%)
208.21M
ENETEthernity Networks Ltd
0.1125p
(2.27%)
207.56M

Discussion

View Full Feed
JERSEYHAWG JERSEYHAWG 6 minutes ago
Mellon. In regard to your post.

I am not the one making trouble for you. Uour really barking up the wrong tree. I have no idea why you single me out as the troublemaker. Cause I sure as heck ain't. It's plain to see your riled up good. But do me a favor and go pick your fight with wh
LEHNQ
crescentmotor crescentmotor 9 minutes ago
But in the case of Blarcamisine, "sufficient" efficacy is up for debate (given the known data).

Granted, the efficacy of Blarcamesine is still under study but, with the favorable peer review, the winds look favorable. And then what else? There's the ever critical safety question wh
AVXL
benz280c benz280c 9 minutes ago
Incorrect and reviling. Do better, please, in 2025.
GDVM
3331 3331 9 minutes ago
BIEL + DR. OZ + RFK = $$$
BIOELECTRONICS FLAGSHIP PRODUCT - ACTIPATCH - ON DR. OZ:
Dr. Oz devoted a whole program to explaining PEMF Pulsed ElectroMagnetic Field technology - with audience members wearing Actipatches (BIEL's flagship product) - saying it is changing the practice of med
IHuser IHuser 10 minutes ago
imo... easier to ban my narrative than counter it........ never going away AZN


AZN



IHuser
AZN
3331 3331 10 minutes ago
BIEL + DR. OZ + RFK = $$$
BIOELECTRONICS FLAGSHIP PRODUCT - ACTIPATCH - ON DR. OZ:
Dr. Oz devoted a whole program to explaining PEMF Pulsed ElectroMagnetic Field technology - with audience members wearing Actipatches (BIEL's flagship product) - saying it is changing the practice of med
harry crumb harry crumb 10 minutes ago
Oh you are from china an part of this scam,you will go down with ILLR when the SEC investigates the fraud of this company
ILLR
martyDg martyDg 11 minutes ago
Damn, I'mma put you now on my ignore list... I'm tired of seeing you stupid conspiracy theories. Effing clown.
NWBO
BDEZ BDEZ 11 minutes ago
“Everything the government says is a lie, and everything it has is stolen” ~ Nietzsche
harry crumb harry crumb 13 minutes ago
There is no desmis you moron fool! Stop lying. Tiktok is #1 an always will be, how can you lie, your mother must keep you in a closet all day with your noony in your mouth you fool
ILLR
stockinspector stockinspector 13 minutes ago
Dad'burn delightful display of doubtful detractors denying, debating and delirious!
WDLF
gawti88 gawti88 13 minutes ago
I wish you were in this riding with us, unfortunately your crew decided to short it for years and you're going to feel the pain now. When we hit 25c, I hope you don't cry.
CEOS
gawti88 gawti88 14 minutes ago
Wait; small company? lmao... dang 95 + employees isn't a small company.
CEOS
JERSEYHAWG JERSEYHAWG 15 minutes ago
Listen to this bro.
I am on no email lists and don't send email lists to anyone. Why? Cause I don't give a Flynn fuk.

That email, of stuff you said you wrote, and I believe it was sent to me. On a rare occasion zi get something sent to me. For instance this time. I don't mess
LEHNQ
jimr1717 jimr1717 15 minutes ago
This blatant scam is done
ILLR
nowwhat2 nowwhat2 17 minutes ago
Why no be just keep go up yet ?

.
XRPUSD
StayHumble StayHumble 17 minutes ago
w0w SEC🔥catches🎅🏿&👽ArtificiallyDeflating Prices 2Buy Shares"


6, 12, 2023 —

SEC charged investment adviser Sabby Management LLC & managing partner,Hal D. Mintz,w/ fraud in connection w/ a long running scheme involving misrepresenta
HMBL
elks elks 19 minutes ago
Wtf.
TWOH
fuagf fuagf 20 minutes ago
Security risk? Shrug. Trump flips on Tik Tok, because it's good for him.

PatriotTakes 🇺🇸
@patriottakes
Nikki Haley comes out against Trump’s plan to save TikTok, but won’t mention him by name

https://pbs.twimg.com/media/GgeV_fjXkAAgNe7?form
XMaster2023 XMaster2023 22 minutes ago
Roman, there could already be deals cut and the only thing we are waiting for now is approval. I actually believe this is the case and NWBO is under a gag order as BP would not want anything getting out until approval.
NWBO
JJ8 JJ8 24 minutes ago
I am encouraged of what I see of the Histogram in the Weekly Chart showing that a new uptrend appears to be in the process of developing for the AMD share price.

Hopefully that is going to continue... and lead to a share price breakout soon.

We shall see.
AMD
boi568 boi568 25 minutes ago
Anavex has delayed PD in order to wait out the development of a reliable biomarker, which has happened only during the past few months. They may also have understandably diverted some resources towards a successful MAA.
AVXL
boi568 boi568 27 minutes ago
There is no regulatory "sufficiency" test, other than being better than the standard of care, if one exists. The article makes the case that blarcamesine is better than any approved AD drug. The FDA employs a risk/benefit analysis, and you want your drug candidate to more than offset any risks with
AVXL

Your Recent History

LSE
BPCR
Biopharma Credit
BIT
S27454
Societe Generale Effekten
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads